March 2026, Vol 16, No 2
Sweeping insurance and policy changes are poised to reshape how patients access and maintain coverage across Medicare, the Marketplace, Medicaid, and the Supplemental Nutrition Assistance Program (SNAP). Read More ›
Imagine you are a healthcare provider seeing a complex patient with symptoms that could point to hundreds of conditions. Read More ›
With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability. Read More ›
On February 12, 2026, the FDA approved Optune Pax, a portable, wearable device that delivers tumor treating fields (TTFields), for the treatment of adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. Read More ›
On February 10, 2026, the FDA approved pembrolizumab (Keytruda) and pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with paclitaxel, with or without bevacizumab, for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumors express PD-L1 (CPS≥1) and who have received 1 or 2 prior systemic treatments. Read More ›
On January 27, 2026, the FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). Read More ›
Medicare’s finalized payment rules introduce a series of technical but consequential changes affecting physician reimbursement, hospital outpatient payment, and oncology coding. Read More ›
January and February have brought significant activity on the pharmacy benefit reform front at the federal level—a long time in coming, but it is not yet time to celebrate. Read More ›